• Home
  • About Us
    Our Approach Our Team Board
  • Pipeline
  • News
  • Honor
  • Careers
  • Collaboration
  • Investor Relations
    Disclosure Contact IR
  • Contact
中文 ENG
    • Home
    • About us
      • Our Approach
      • Our Team
      • Board
    • Pipeline
    • News
    • Honor
    • Careers
    • Collaboration
    • Investor Relations
      • Disclosure
      • Contact IR
    • Contact
    • CN

COMPANY NEWS

Category Company News Enterprise Honor
2025 10

20

ESMO 2025 || TYK Medicines Releases Positive Clinical Data on Multiple CDK Inhibitors

Discover More
2025 08

14

TYK Medicines, Inc.’s EGFR-Targeted Innovative Drug Asandeutertinib Demonstrates Excellent Efficacy in NSCLC Patients with Brain Metastases — Interim Results from the ESAONA Pivotal Study Announced at WCLC 2025

Discover More
2025 04

24

Asandeutertinib (TY-9591) Submitted for Pre-New Drug Application

Discover More
2025 04

16

JTO Published Phase I Study Results of Asandeutertinib Mesylate Tablets

Discover More
2025 02

25

TYK Medicine’s CDK7 Inhibitor TY-2699a Receives CDE Clinical Approval for Combination Therapy

Discover More
2025 02

25

TYK Medicine’s CDK2 Inhibitor Receive Clinical Approval from CDE for Combination Therapy

Discover More
12345>
CN ENG
  • Home
  • About Us
  • Pipeline
  • News
  • Honor
  • Careers
  • Investors
  • Contact
Powered by SE

Copyright © 2019 浙江同源康 版权所有 浙ICP备19008464号